Gilead Sciences' Two Phase Three Trials Meet Primary Endpoints
April 15, 2016 at 06:53 AM EDT
Gilead Sciences, Inc. (NASDAQ: GILD) disclosed detailed 48-week results of its two big phase three clinical trials to evaluate ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.